A Phase 2b Randomized, Double-blind, Placebo-Controlled Study of Evaluate and Efficacy of MEDI8897, a Monoclonal Antibody with an extended Half-life Against Respiratory Syncytial Virus in Healthy Preterm Infants

  • Patel, Janak (PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/28/16 → 10/27/19

Funding

  • AstraZeneca LP: $7,500.00